v3.26.1
Collaboration, License and Option Agreements - Abbvie (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 01, 2025
USD ($)
shares
Jun. 30, 2026
USD ($)
shares
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Feb. 28, 2025
USD ($)
Program
$ / shares
Agreements              
Common stock issued and sold (in shares) | shares   592,300          
Revenue   $ 18,692 $ 8,084 $ 31,340 $ 11,014    
Revenue from Contract with Customer, Product and Service   Collaboration And License Member Collaboration And License Member Collaboration And License Member Collaboration And License Member    
Deferred revenue   $ 35,318   $ 35,318   $ 60,658  
Deferred revenue, current portion   22,603   22,603   40,023  
AbbVie Stock Purchase Agreement              
Agreements              
Common stock issued and sold (in shares) | shares 310,559            
Purchase price (in dollars per share) | $ / shares             $ 32.2
Development milestone related payment   6,000   6,000   5,000  
Transaction price             $ 7,100
AbbVie              
Agreements              
Gross proceeds from issuance of private placement $ 10,000            
Collaboration and Stock Purchase Agreement | AbbVie              
Agreements              
Additional program initiation period 3 years            
Gross proceeds from issuance of private placement       10,000      
Development milestone related payment       5,000      
Additional development milestone achieved       6,000      
Upfront payment       57,000      
Upfront payment, cash       42,000      
Maximum additional contingent payments receivable       2,100,000      
Maximum additional contingent payments receivable, Fees       305,000      
Maximum additional contingent payments receivable, Milestones       1,800,000      
Fair market value of common stock issued (in dollars)             2,900
Premium of common stock issued (in dollars)             7,100
Transaction price             $ 42,000
Revenue   12,700 $ 4,800 5,600 $ 20,700    
Deferred revenue   19,281   19,281   $ 34,007  
Collaboration and Stock Purchase Agreement | AbbVie | Maximum              
Agreements              
Number of programs | Program             4
Number of additional programs | Program             2
Initial Option Program, Material right for counterparty's right to substitute initial target with backup target | AbbVie              
Agreements              
Transaction price             $ 500
Initial Option Program, Right to receive additional services | AbbVie              
Agreements              
Transaction price             1,100
Initial Option Program, Material right to receive an exclusive license | AbbVie              
Agreements              
Transaction price             8,200
Initial Option Program Performance Obligation | AbbVie              
Agreements              
Transaction price             6,900
Collaboration Program Performance Obligation | AbbVie              
Agreements              
Transaction price             32,400
Collaboration Agreement | AbbVie              
Agreements              
Transaction price             $ 49,100
Deferred revenue   19,300   19,300      
Deferred revenue, current portion   $ 9,400   $ 9,400